Ardelyx (NASDAQ:ARDX) Share Price Passes Below Fifty Day Moving Average – Time to Sell?

Posted by Stanley Muller on Jul 9th, 2026

Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) shares crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.96 and traded as low as $5.26. Ardelyx shares last traded at $5.43, with a volume of 3,561,974 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. LADENBURG THALM/SH SH assumed coverage on Ardelyx in a research report on Tuesday, June 16th. They issued a “buy” rating and a $16.00 target price on the stock. Leerink Partners reiterated an “outperform” rating on shares of Ardelyx in a research note on Thursday, March 12th. Weiss Ratings cut Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. Finally, Williams Trading set a $17.00 target price on shares of Ardelyx in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.73.

Check Out Our Latest Analysis on ARDX

Ardelyx Trading Up 0.9%

The company has a current ratio of 3.49, a quick ratio of 3.28 and a debt-to-equity ratio of 1.37. The stock has a market cap of $1.34 billion, a P/E ratio of -23.61 and a beta of 0.61. The company has a 50-day moving average price of $5.96 and a two-hundred day moving average price of $6.27.

Ardelyx (NASDAQ:ARDX – Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Ardelyx had a negative net margin of 13.58% and a negative return on equity of 38.11%. The firm had revenue of $94.47 million during the quarter, compared to analysts’ expectations of $92.78 million. During the same period in the prior year, the company posted ($0.17) EPS. The company’s revenue was up 27.5% compared to the same quarter last year. On average, research analysts expect that Ardelyx, Inc. will post -0.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mike Kelliher sold 7,248 shares of Ardelyx stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the sale, the insider owned 357,418 shares of the company’s stock, valued at approximately $2,241,010.86. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric Duane Foster sold 7,998 shares of Ardelyx stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total value of $50,147.46. Following the sale, the insider directly owned 417,972 shares of the company’s stock, valued at approximately $2,620,684.44. This trade represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 24,572 shares of company stock worth $154,066. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Ardelyx by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,061 shares of the biopharmaceutical company’s stock worth $781,000 after buying an additional 4,436 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Ardelyx by 10.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company’s stock worth $11,680,000 after acquiring an additional 221,486 shares in the last quarter. Focus Partners Wealth acquired a new stake in Ardelyx in the 1st quarter worth approximately $72,000. Strs Ohio purchased a new stake in shares of Ardelyx during the first quarter valued at $135,000. Finally, Legal & General Group Plc grew its stake in Ardelyx by 13.5% during the 2nd quarter. Legal & General Group Plc now owns 275,344 shares of the biopharmaceutical company’s stock valued at $1,080,000 after purchasing an additional 32,738 shares during the last quarter. Institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

(Get Free Report)

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.